Every Form 4 that KalVista Pharmaceuticals, Inc. (KALV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KALV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KALV filings page.
KalVista Pharmaceuticals (KALV) reported insider activity by CEO Benjamin L. Palleiko. On 11/11/2025, 7,120 RSUs vested and were settled into common stock. On 11/12/2025, he sold 3,328 shares at $11.55 to cover tax withholding tied to the RSU settlement. Following these transactions, directly held common stock was 398,981 shares, and derivative securities beneficially owned were 106,800. The RSU award vests in equal quarterly installments beginning November 11, 2025.